Siremadlin
- Generic Name
- Siremadlin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24Cl2N6O4
- CAS Number
- 1448867-41-1
- Unique Ingredient Identifier
- 0282IF4JC8
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Phase 1
Completed
- Conditions
- Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 298
- Registration Number
- NCT02890069
- Locations
- ๐บ๐ธ
Huntsman Cancer Institute, Salt Lake City, Utah, United States
๐ฌ๐งNovartis Investigative Site, Oxford, United Kingdom
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT02343172
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Taipei, Taiwan
Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
Phase 1
Completed
- Conditions
- Advanced Solid and Hematological TP53wt Tumors
- Interventions
- Drug: ancillary treatment
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 208
- Registration Number
- NCT02143635
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan
๐บ๐ธDana Farber Cancer Institute SC-6, Boston, Massachusetts, United States
๐บ๐ธMemorial Sloan Kettering Onc. Dep, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath